The TET2 Expression Level Correlates with a Short Relapse Time in Glioblastoma Multiforme

Josephine Briand 1, 2, 3, 4 Arulraj Nadaradjane 1, 2, 3, 4 François Vallette 1, 2, 4, 5 Pierre Cartron 1, 2, 3, 4, 5, *
* Corresponding author
1 CRCINA - Département ONCO - Equipe 9 - Apoptosis and tumor progression -ATP
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
2 LabCT - Laboratoire de Biologie des Cancers et de Théranostic [St Herblain, Nantes]
3 REpiCGO - Réseau Epigénétique du Cancéropôle Grand-Ouest [Nantes]
4 EpiSAVMEN - Epigénétique - Santé - AgroAlimentaire - Végétal - Mer - Environnement - Nutrition [Nantes]
5 LabEx IGO “Immunotherapy, Graft, Oncology” [Nantes]
Abstract : Background: Epigenetic changes play crucial roles in cancer initiation and progression and in tumor recurrence. Glioblastoma multiforme (GBM) is by far the most common and most malignant of the glial tumors, and its recurrence is ineluctable. Thus, anti-GBM therapy need for new treatments for recurrent GBM. We here in focused on identifying whether TET2 (an epigenetic players involving in the DNA demethylation process) as a putative target for the development of anti-GBM therapy. Results: We observed that the expression level of TET2 at mRNA and protein levels is not associated with a prognosis value of survival in GBM patients. However, in a cohort of 10 GBM patients having received two surgical resections (rGBM), we noted that three in ten rGBM patients have an increase of TET2 expression between resection#1 and #2. Conclusions: By observing an increase of TET2 expression between two surgical resections an despite the fact that expression level of TET2 is devoid of prognosis value of survival in GBM patients, our data provide a promising starting point for the use of TET2 inhibitors administrable in the subgroup of patients with recurrent GBM.
Keywords : DNA methylation TET TET2 Glioblastoma multiforme TET inhibitors
Document type :
Journal articles
Complete list of metadatas

Cited literature [20 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-01981842
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, January 15, 2019 - 11:50:27 AM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM
Long-term archiving on : Tuesday, April 16, 2019 - 2:05:34 PM

File

JournalOfClinicalEpigenetics20...
Publication funded by an institution

Identifiers

Collections

UNIV-ANGERS | CRCINA | UNIV-NANTES

Citation

Josephine Briand, Arulraj Nadaradjane, François Vallette, Pierre Cartron. The TET2 Expression Level Correlates with a Short Relapse Time in Glioblastoma Multiforme. Journal of Clinical Epigenetics / J Clin Epigenet, Wilmington, DE : iMedPub, 2018, 04 (02), pp.12. ⟨10.21767/2472-1158.100097⟩. ⟨inserm-01981842⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

85

Files downloads

158

Contact

CCSD